Research at Oslo University Hospital
Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
First author Kristina Berg Lorvik and senior author Alexandre Corthay
Collaborative efforts by researchers at the Department of Immunology and the Department of Pathology revealed the unexpected potential of tumor-specific Th2 cells for cancer immunotherapy by adoptive cell transfer (ACT) in mice.
The study was published in the December 1st 2016 issue of Cancer Research, the flagship journal of the American Association for Cancer Research. An immunofluorescence microscopy image from the paper was selected to illustrate the journal cover.
Two skilful and talented scientists have recently been appointed group leaders at the Department of Molecular Cell Biology at the Institute for Cancer Research.
Jorrit Enserink (left) heads the "Dynamic responses to cell stress" group. He was previously affiliated to the Department of Microbiology at the Division of Laboratory Medicine, OUS.
Tor Erik Rusten is heading the "Tumor-Host Biology" group, and has been promoted from his previous project group leader status at the same department.
In order to stimulate excellent research and draw attention to the hospital's extensive research activity, Oslo University Hospital reward outstanding publications regularly.
Six research groups were awarded for their excellent papers published during the first half-year of 2016 during a ceremony November 18th. Each group received NOK 50.000 for use in further research. The prize winners gave short presentations of the main findings in their respective articles.
The six selected articles are of especially high quality, and they present important finding on both-short and long-term scales. The works reflect the good quality and the interdisciplinarity that characterises several research environments at Oslo University Hospital. The research is a fundamental condition for the institution to maintain and strenghten the quality in the patient treatment.
The 2016 "Dr. Ragnar Mørk's legacy prize" went to Therese Sørlie, head of the "Breast tumor initiation and progression group" at the Department of Cancer Genetics. This award of NOK 200.000 is annually given to scientists affiliated to the Norwegian Radium Hospital who have obtained important results within the field of cancer research. The ceremony took place on Friday November 18th in the Research Building at Montebello.
Therese Sørlie gave a lecture about the research activities that has earned her the award.
Kristian Berg, the founder of the intracellular drug delivery technology photochemical internalisation (PCI) recently co-authored a paper that were published in Lancet Oncology (journal impact factor 24.69) together with collaborators at the University College London (UCL) Hospitals, London where the study was conducted and PCI Biotech.
The article "Disulfonated tetraphenyl chlorin (TPCS2a)-induced photochemical internalisation of bleomycin in patients with solid malignancies: a phase 1, dose-escalation, first-in-man trial" was also commented in the same issue of Lancet Oncology.
The classical view of tissue macrophages is that they are continuously replaced by blood monocytes, but a paper first-authored by Ibon Eguiluz-Gracia (photo) from Frode Jahnsen's group at the Department of Pathology at OUH and the Centre for Immune Regulation at UiO, recently published in Thorax (journal impact factor 8.3), show that human alveolar macrophages are self-maintained within the lungs for many years. This may be important for development of chronic graft rejection, which is a common complication after lung transplantation and remains the major obstacle to better long-term outcomes.
Furthermore, as pointed out in the accompanying Editorial in Thorax, this study has potential implications for treatment of patients with alveolar proteinosis and COPD.
The Norwegian Cancer Society has recently distributed in total 179 million NOK to Norwegian cancer researchers. The 34 projects that will receive funding are distributed among seven research institutions in Tromsø, Trondheim, Bergen and Oslo. Twelve research groups are affiliated to Oslo University Hospital. OUH project leaders being supported are Svein Dueland, Jon Amund Kyte, Heidi Lyng, Eirik Malinen, Johanna Olweus, Mouldy Sioud, Erlend Bremertun Smeland, Harald Stenmark, Bjørn Atle Bjørnbeth, Magnar Bjørås, Alexandre Corthay and Jorrit Enserink, and these will altogether receive 77.3 million NOK.
Dag Berild from the Department of Infectious Diseases at the Division of Medicine has recently been awarded the "Akademikerprisen".
Berild receives the prize for his important work within the field of antibiotic resistance, which is considered one of the major global Health threats of today.
The "Akademikerprisen" will be distributed during the Akademikernes fall Meeting October 27th. Berild will here receive a sculpture from the artist Nico Widerberg and a sum amounting to 100.000 NOK.
Mouldy Sioud (photo) from the Department of Immunology at the Instiute for Cancer Research is senior author on an article recently published in Oncotarget (journal impact factor 6.36), entitled "Cancer cell-binding peptide fused Fc domain activates immune effector cells and blocks tumor growth".
Lina Prasmickaite from the Department of Tumor Biology at the Institute for Cancer Research has spent several years studying why certain cancer cells become immune against treatment. Her research on this subject is presented in a popular science article (in Norwegian) recently published by the Norwegian Cancer Society.
Jon-Vidar Gaustad – Dept. of Radiation Biology
Nov 29, 2016
Selected latest publications
Journ. Impact factor > 8 First or last author from Oslo University Hospital
Basophils promote tumor rejection via chemotaxis and infiltration of CD8+ T cells
Cancer Res (in press)
Consistent Functional Connectivity Alterations in Schizophrenia Spectrum Disorder: A Multisite Study
Schizophr Bull (in press)
Arrhythmogenic Right Ventricular Cardiomyopathy: Better Tools for Detecting Early Disease and Progression
J Am Coll Cardiol, 68 (20), 2198-2200
More selected publications